Elron Ventures Ltd · TASE:ELRN

Elron Ventures — Investor Presentation (August 2013)

25 slides from Elron Ventures's investor presentation, August 2013

  1. Slide 1: Investor Presentation August 2013

    INVESTOR PRESENTATION / AUGUST 2013

  2. Slide 2: Forward-Looking Information

    Forward-Looking Information This presentation is for information purposes only. By this presentation, Elron does not intend to solicit offers to purchase its securities and the presentation does not constitute an invitation to receive such offers. Elron may make improvements and/or changes in the fe

  3. Slide 3: Elron Q2/13 Highlights

    ELRON Q2/13 > HIGHLIGHTS ELRON

  4. Slide 4: Q2/13 Highlights

    ELRON Q2/13 > HIGHLIGHTS  GIVEN IMAGING: Record sales during Q2/13- sales amounted to $49.5m, compared with sales of $44.5m in Q2/12, an 11% increase.  The PillCam COLON 2 received marketing clearance in Japan. Given Imaging expects reimbursement may become effective during the first half of 2014.

  5. Slide 5: Elron 2013

    ELRON 2013 > CATALYSTS ELRON

  6. Slide 6: Major Group Holdings

    ELRON 2013 > CATALYSTS MAJOR GROUP HOLDINGS Business Shareholdings Elron’s investment world leader in GI medical devices and pioneer 30% of capsule endoscopy (8.43% by RDC) NA real-time & automated microbiology laboratory system 41% $26m treatment of ischemic stroke in 24h window post symptom onset

  7. Slide 7: BrainsGate: Elron 2013 Catalysts

    ELRON 2013 > CATALYSTS  Elron’s holding: 30%  Founded: 2000  First investment by Elron: 2005  ~$70m have been invested to date, of which ~$21m by Elron  Main partners: Johnson & Johnson, Boston Scientific, Pitango, Cipio Partners  Device for treating ischemic stroke in 24 hour window post symp

  8. Slide 8: Why 24 Hours?

    ELRON 2013 > CATALYSTS WHY 24 HOURS? tPA (current treatment): SPG stimulation: dissolve clot augment cerebral blood flow  Restores blood flow to the blocked  Electrical stimulation induces blood vessel dilation of cerebral blood vessels, and thus augments blood flow  Due to the temporary interrup

  9. Slide 9: Implant and Implantation Site

    ELRON 2013 > CATALYSTS IMPLANT AND IMPLANTATION SITE

  10. Slide 10: Catalyst 2013

    ELRON 2013 > CATALYSTS  In 2010 BrainsGate completed a clinical trial on approximately 300 patients, whose results strengthened the assessment that BrainsGate’s treatment has a considerable clinical effect, which is stronger than the effect found in current treatments.  Since June 2011, BrainsGate

  11. Slide 11: Pocared: Elron 2013 Catalysts

    ELRON 2013 > CATALYSTS  Elron’s holding: 41%  Founded: 2004  First investment by Elron: 2007  ~$64m have been invested to date, of which ~$26m by Elron  Main partner: SCP Vitalife  Real-time and automated microbiology laboratory system, using optical technology  The system is designed for use

  12. Slide 12: Diagnosis in Under 20 Minutes

    ELRON 2013 > CATALYSTS DIAGNOSIS IN UNDER 20 MINUTES: urine sample a complete move carousel to cartridge cartridge carousel sample prep module move carousel to optical analyzer results… module

  13. Slide 13: Catalyst 2013

    ELRON 2013 > CATALYSTS  In December 2011, the company received CE certification.  Pocared commenced urine sample collection for a diagnostic trial to prove the efficacy of its system's first application, UTI diagnosis. The trial is expected to support its planned FDA submission. The diagnostic tri

  14. Slide 14: Given Imaging: Catalysts 2013

    ELRON 2013 > CATALYSTS  Market cap - ~$520m (August 2013)  Q2/13 revenues - $49.5m ;2012 revenues - $181m  Cash and financial assets - ~$130m (as of June 30, 2013)  In the United States, Given Imaging completed an 885-patient, multi- center pivotal clinical trial with the PillCam COLON 2 capsule

  15. Slide 15: PillCam COLON 2

    ELRON 2013 > CATALYSTS PILLCAM COLON 2: Sources: http://www.guideline.gov/content.aspx?id=14346; http://www.webmd.com/colorectal-cancer/which-test-should-i-have-to-screen-for- colorectal-cancer#zx3796; Lieberman D. Screening for colorectal cancer. New England Journal of Medicine. 2009: 361;12; Spada

  16. Slide 16: Elron 2014+

    ELRON 2014 + CARTIHEAL NOTAL VISION KYMA

  17. Slide 17: CartiHeal: Elron 2014+

    ELRON 2014+  Elron’s holding: 24%  Founded in 2009; First investment by Elron in 2012.  $7.85m invested in company to date, including $2.5m by Elron.  Other investors include Accelmed (owned by Mori Arkin) and Access Medical Ventures.  Implants for repairing cartilage and osteochondral defects

  18. Slide 18: CartiHeal results post-op

    ELRON 2014+ 1 day post-op: 6 months post-op:

  19. Slide 19: Notal Vision: Elron 2014+

    ELRON 2014+  Elron’s holding : 23%  Founded in 2000; First investment by Elron in 2003.  $27m invested in company to date, including $6.5m by Elron.  Remote monitoring of patients at risk of vision loss from AMD.  AMD destroys sharp, central vision, necessary for common tasks such as facial rec

  20. Slide 20: Kyma: Elron 2014+

    ELRON 2014+  Elron’s holding (through RDC): 37%  Founded in 2008; First investment by Elron in 2009.  $7.5m invested in company to date.  Miniature device for the continuous remote monitoring of chronic heart failure (CHF) patients, inserted beneath the skin or attached to the patient’s torso in

  21. Slide 21: Elron Q2/13 Financials

    ELRON Q2/13 > FINANCIALS ELRON

  22. Slide 22: Public Holdings and Financials

    ELRON Q2/13 > FINANCIALS Public Holdings 1 ($m) (Market value as of Aug. 12, 2013) Given Imaging 132.9 Other holdings 0.4 Total Public Holdings 133.3 Private Holdings 1 (Book value as of June 30, 2013) Pocared 3.0 BrainsGate 1.9 Jordan Valley 11.4 Other holdings 2 13.7 Total Private Holdings 30.0 Fi

  23. Slide 23: Quote from Elron's founder Uzia Galil

    “ Looking ahead, Elron should always understand that the ever evolving changes in the high tech industry will be exponential, and therefore, success will depend on choosing the right niches in the world market in which it can maintain and improve its relative advantage. Mr. Uzia Galil, Elron’s found

  24. Slide 24: The Bottom Line

    ELRON > THE BOTTOM LINE  Unique access to Israel’s world-class human capital, R&D resources, universities, & scientific institutions  An operational holding company with the ability to provide long-term commitment to group companies  Strategic alliance with Rafael and access to state of the art m

  25. Slide 25: Visit us at elron.com

    visit us at elron.com

Elron Ventures — Investor Presentation (August 2013) on 6ix